TY - JOUR
T1 - Effects of guanfacine extended release on oppositional symptoms in children aged 612 years with attention-deficit hyperactivity disorder and oppositional symptoms
T2 - A randomized, double-blind, placebo-controlled trial
AU - Connor, Daniel F.
AU - Findling, Robert L.
AU - Kollins, Scott H.
AU - Sallee, Floyd
AU - Lpez, Frank A.
AU - Lyne, Andrew
AU - Tremblay, Gerald
N1 - Funding Information:
Dr Frank A. López is a consultant for Celltech, Cephalon, Eli Lilly, New River, Novartis and Shire Pharmaceuticals, Inc. He has received honoraria from Novartis and Shire Pharmaceuticals, Inc. He has received grants from Bristol-Myers Squibb, Celltech, Cephalon, New River, Novartis, Pfizer and Shire Pharmaceuticals Inc.
Funding Information:
Dr Daniel F. Connor receives honoraria and grant research support from Shire Pharmaceuticals, Inc. and is a speaker, consultant and is on the advisory board for Shire Pharmaceuticals, Inc. He also receives support from NIMH and the State of Connecticut, USA.
Funding Information:
This clinical research was funded by Shire Development Inc. Authors directed writing assistance from Jennifer Steeber, PhD, an employee of Health Learning Systems. Editorial assistance in the form of proofreading, copy editing and fact checking was also provided by Health Learning Systems. Health Learning Systems was funded by Shire Development Inc. for authorship support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation and fact checking of information, the ultimate interpretation was made by the independent authors, as was the content of this manuscript and the decision to submit it for publication in CNS Drugs.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2010
Y1 - 2010
N2 - Objective: To evaluate the efficacy and safety of guanfacine extended release (XR, Intuniv™ Shire Development Inc., Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 years with a diagnosis of attention-deficit hyperactivity disorder (ADHD) and the presence of oppositional symptoms. Subjects and Methods: In this randomized, double-blind, placebo-controlled, multicentre, flexible-dose, dose-optimization study, children aged 6-12 years were randomized to receive guanfacine XR (1-4mg/day) or placebo for 9 weeks. Screening and washout periods were followed by a 5-week dose-optimization period, a 3-week dose-maintenance period and a 1-week tapering period. The primary efficacy measure was change from baseline to endpoint in the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) score. Change in ADHD Rating Scale IV (ADHD-RS-IV) total score was a secondary efficacy measure. Safety assessments included adverse events (AEs), vital signs, ECG readings and laboratory studies. Results: A total of 217 children were enrolled: 138 were randomized to receive guanfacine XR and 79 to receive placebo. Least-squares mean reductions from baseline to endpoint in CPRS-R:L oppositional subscale scores were 10.9 in the guanfacine XR group compared with 6.8 in the placebo group (p < 0.001; effect size = 0.59). A significantly greater reduction in ADHDRS-IV total score from baseline to endpoint was also seen in the guanfacinetreated group compared with the placebo group (23.8 vs 11.5, respectively; p < 0.001; effect size = 0.92). A post hoc correlation analysis between percentage reduction from baseline to endpoint in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores indicated that the decreases in oppositional symptoms and ADHD symptoms were highly correlated (r = 0.74). The most commonly reported, treatment-emergent AEs (TEAEs) in the guanfacine XR group were somnolence (50.7%), headache (22.1%), sedation (13.2%), upper abdominal pain (11.8%) and fatigue (11.0%) and most were mild or moderate in severity. TEAEs of sedation, somnolence or hypersomnia were experienced by 62.5% of subjects in the guanfacine XR group. These events were most common during the dose-titration period but most (63.5%) resolved prior to the taper period. TEAEs of fatigue, lethargy and asthenia were reported in 11.0%, 3.7% and 0.0% of subjects in the guanfacine XR group, respectively. Most subjects receiving guanfacine XR demonstrated modest changes in blood pressure, pulse rate and ECG readings that were not considered clinically significant. Conclusions: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms.
AB - Objective: To evaluate the efficacy and safety of guanfacine extended release (XR, Intuniv™ Shire Development Inc., Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 years with a diagnosis of attention-deficit hyperactivity disorder (ADHD) and the presence of oppositional symptoms. Subjects and Methods: In this randomized, double-blind, placebo-controlled, multicentre, flexible-dose, dose-optimization study, children aged 6-12 years were randomized to receive guanfacine XR (1-4mg/day) or placebo for 9 weeks. Screening and washout periods were followed by a 5-week dose-optimization period, a 3-week dose-maintenance period and a 1-week tapering period. The primary efficacy measure was change from baseline to endpoint in the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) score. Change in ADHD Rating Scale IV (ADHD-RS-IV) total score was a secondary efficacy measure. Safety assessments included adverse events (AEs), vital signs, ECG readings and laboratory studies. Results: A total of 217 children were enrolled: 138 were randomized to receive guanfacine XR and 79 to receive placebo. Least-squares mean reductions from baseline to endpoint in CPRS-R:L oppositional subscale scores were 10.9 in the guanfacine XR group compared with 6.8 in the placebo group (p < 0.001; effect size = 0.59). A significantly greater reduction in ADHDRS-IV total score from baseline to endpoint was also seen in the guanfacinetreated group compared with the placebo group (23.8 vs 11.5, respectively; p < 0.001; effect size = 0.92). A post hoc correlation analysis between percentage reduction from baseline to endpoint in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores indicated that the decreases in oppositional symptoms and ADHD symptoms were highly correlated (r = 0.74). The most commonly reported, treatment-emergent AEs (TEAEs) in the guanfacine XR group were somnolence (50.7%), headache (22.1%), sedation (13.2%), upper abdominal pain (11.8%) and fatigue (11.0%) and most were mild or moderate in severity. TEAEs of sedation, somnolence or hypersomnia were experienced by 62.5% of subjects in the guanfacine XR group. These events were most common during the dose-titration period but most (63.5%) resolved prior to the taper period. TEAEs of fatigue, lethargy and asthenia were reported in 11.0%, 3.7% and 0.0% of subjects in the guanfacine XR group, respectively. Most subjects receiving guanfacine XR demonstrated modest changes in blood pressure, pulse rate and ECG readings that were not considered clinically significant. Conclusions: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms.
KW - Adrenergic-receptor-agonists
KW - therapeutic
KW - therapeutic use Alpha-2-adrenergic-receptor- agonists
UR - http://www.scopus.com/inward/record.url?scp=77956222823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956222823&partnerID=8YFLogxK
U2 - 10.2165/11537790-000000000-00000
DO - 10.2165/11537790-000000000-00000
M3 - Article
C2 - 20806988
AN - SCOPUS:77956222823
SN - 1172-7047
VL - 24
SP - 755
EP - 768
JO - CNS Drugs
JF - CNS Drugs
IS - 9
ER -